Jaguar Health Inc. $(JAGX)$ has announced progress in the development of its novel crofelemer powder formulation for oral solution, intended for the treatment of microvillus inclusion disease (MVID), an ultrarare pediatric disorder. Following a recent Type C Meeting with the U.S. Food and Drug Administration (FDA), the company reported constructive discussions regarding the clinical trial pathway for potential approval of crofelemer for this indication. Results from an ongoing investigator-initiated proof-of-concept trial in the United Arab Emirates demonstrate an approximate 37% reduction in total parenteral support among participants. Jaguar Health has previously received orphan drug designations for crofelemer for MVID from both the FDA and the European Medicines Agency. Further discussions with regulatory agencies in the European Union and the Middle East/North Africa region are planned. The company indicated that selected amendments will be made to the clinical study based on FDA feedback, and additional results will be presented as the trial progresses.